ReviewRevista medica del Instituto Mexicano del Seguro Social2025
[Perinatal benefits and recommendations of docosahexaenoic acid and arachidonic acid].
Review in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Docosahexaenoic acid (DHA) and arachidonic acid (AA) are fatty acids, part of the human milk composition. Their concentrations depend on maternal diet and endogenous supply, but recommended levels are not often reached. Objective: Support with evidence the DHA and AA benefits and recommendations for the infant, during pregnancy and breastfeeding. Material and methods: Narrative review. Search was made using the keywords: recomendaciones, inflamación, inmunidad, ácidos grasos, omega-3, DHA, leche materna, pretérmino, embarazo, recién nacido, suplementación; as well LC-PUFA, human milk, preterm, immunity, DHA, pregnancy, supplementation, recommendations, from 2020-2024; if there was no information in this period, the up-to-date reference was reported. Results: DHA recommendations during pregnancy and breastfeeding: 200-450 mg/day; if the DHA tissue reserve was low in pregnancy, administer 1,000 mg/day. In the preterm infant: 30-100 mg of AA/kg/day; 30-65 mg of DHA/kg/day. Infant 7-23 months 100 mg of DHA/kg/day. Covering the supply through food or supplements during gestation and after birth improves the development and functioning of the immune, brain, and visual systems in the child, modulates the inflammatory response, and reduces the risk of premature birth and neonatal diseases. Conclusion: Assuring the DHA and AA supply promotes optimal development and may prevent diseases in the infant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.